hsa-miR-100

ncRNA information

ncRNA name

hsa-miR-100

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

mTOR

Cancer information

Cancer name

Chondrosarcoma

Cancer site

Pelvis, Hip and Shoulder

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Down

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MicroRNA-100 Resensitizes Resistant Chondrosarcoma Cells to Cisplatin through Direct Targeting of mTOR.

Tissue resource

primary human chondrosarcoma specimens

normal human chondrocyte cell lines C-28/l2

normal human chondrocyte cell lines CHON-001

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

Zaozhuang Municipal Hospital Cancer Center

Country

China

Continent

Asia